Skip to main content
Last Updated
In the Matter of Endo Health Solutions Inc., a corporation; Boca Life Science Holdings, LLC, a limited liability company; and Boca Pharmacal, LLC, a limited liability company
FTC Matter/File Number
131 0225
Docket Number
Enforcement Type
Part 2 Consents

Case Summary

Pharmaceutical companies Endo Health Sciences Inc. (Endo) and Boca Life Science Holdings, LLC and Boca Pharmacal, LLC (Boca) agreed to a settlement resolving FTC charges that Endo’s acquisition of Boca would be anticompetitive. Under the settlement, the companies will relinquish their rights to market and distribute four generic multivitamin fluoride drops for children, and will sell three other generic drugs in development.The proposed settlement preserves competition in the pharmaceutical markets for four prescription generic multivitamin drop products given to children in the United States who do not have access to fluoridated water.  In addition, the FTC’s settlement preserves future competition for three generic drugs where the proposed acquisition would eliminate one likely future entrant from a very limited pool of future entrants.